Results 181 to 190 of about 137,616 (341)

Tumor‐infiltrating B cells participate in shaping the immunosuppressive microenvironment in solid tumors

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Tumor‐infiltrating B cells (TIBs) exhibit dual roles in the tumor microenvironment (TME) of solid tumors. While they can enhance anti‐tumor immunity through antibody production and immune activation, certain subsets—such as regulatory B cells (Bregs) and immunosuppressive plasma cells—contribute to immune evasion by secreting inhibitory ...
Zhitong Li   +5 more
wiley   +1 more source

Effect of Naringenin on Potassium Bromate–Induced Hepatotoxicity In Vivo: A Dose‐Dependent Study

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT Potassium bromate (PB) is a well‐known additive in the food industry and a byproduct of water treatment. Its long‐term exposure to any form of life exerts mild to severe toxic insults in a dose‐dependent fashion and can even trigger carcinogenesis.
Iftekhar Hassan   +6 more
wiley   +1 more source

Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView., 2023
Abstract Despite 2 h of daily exercise training, muscle wasting and bone loss are still present after 6‐month missions to the international space station. Some crew members lose bone much faster than others. In preparation for missions to the Moon and Mars, space agencies are therefore reviewing their countermeasure portfolios.
Friederike Thomasius   +2 more
wiley   +1 more source

Early Hepatotoxicity of Methotrexate in Rheumatoid Arthritis

open access: bronze, 1970
Mahmood Parvin   +3 more
openalex   +2 more sources

In Vitro Assessment of Drug‐Induced Liver Injury Using Three‐Dimensional Cultured HepaSH Cells Derived From Chimeric Mouse Model With Humanized Liver

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT Drug‐induced liver injury (DILI) is a serious adverse event and a common cause of postmarketing drug withdrawal. Despite nonclinical assessments of DILI risk, which are predominantly conducted in experimental animals, DILI remains a frequent adverse event, highlighting the need to improve nonclinical assessments.
Xingming Liu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy